

LifeView™

**M2**

**Miscarriage  
Risk Study**



**Genomic Prediction**  
Clinical Laboratory


Genomic Prediction is conducting an observational study to determine how patients' M2 carrier status is associated with history of pregnancy complications, and the utilization and outcomes of interventions available to carrier couples.

M2 is a genetic variant that increases the risk of placental mediated pregnancy loss and complications such as pre-eclampsia and miscarriage during pregnancy.


Treatment may include the use of low molecular weight heparin (LMWH) injections during pregnancy or the use of a newly developed test to detect the M2 variant in embryos and select non-carrier embryos for transfer.

### M2 is a mutation in the Annexin A5 gene.

Some patients undergoing IVF are struggling with infertility. M2 may be a part of that equation.



### M2 carriers have:



Participation in the study is fast and easy. Patients who are over the age of 18 and can provide a saliva sample from both the biological parents of the embryos are eligible to participate.



Patients who elect to participate will have parental M2 carrier testing performed free of charge.


A report will be issued to you with your results. As part of your study participation your medical history will be collected.



For carrier couples, your decisions and outcomes of electing for LMWH treatment, use of the newly developed embryo testing, or no intervention will also be monitored and recorded.



Patients who elect to use Preimplantation Genetic Testing (PGT) can obtain PGT for embryonic M2 carrier status without paying fees above traditional PGT-A (aneuploidy) costs.





**Genomic Prediction**  
Clinical Laboratory

+1 (973) 529 4223    675 US Highway One,  
contact@gpclaboratory.com    North Brunswick, NJ  
gpclaboratory.com    08902